Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 7785 results

  1. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Awaiting development [GID-TA11467] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Natural Cycles for monitoring fertility

      Status ...

    Medical technologies guidance
    Topic selection

  3. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  4. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development [GID-TA10832] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

    In development [GID-TA11587] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  7. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Non-alcoholic fatty liver disease (NAFLD): assessment and management

    In development [GID-NG10434] Expected publication date: TBC

    NICE guideline
    In development

  9. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    In development [GID-TA10893] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Zuranolone for treating postnatal depression [ID6431]

    In development [GID-TA11356] Expected publication date: 15 October 2025

    Technology appraisal guidance
    In development

  11. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development [GID-TA11424] Expected publication date: 15 October 2025

    Technology appraisal guidance
    In development

  12. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development [GID-TA11103] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]

    In development [GID-TA10969] Expected publication date: 15 October 2025

    Technology appraisal guidance
    In development

  15. Iptacopan for treating complement 3 glomerulopathy ID6283

    In development [GID-TA11331] Expected publication date: 08 January 2026

    Technology appraisal guidance
    In development